US FDA asks Stealth BioTherapeutics to resubmit application for rare genetic condition therapy

The FDA has requested Stealth BioTherapeutics to resubmit its marketing application for elamipretide, a therapy targeting the rare genetic condition Barth syndrome, marking a setback after previous delays. The FDA is hesitant to extend accelerated approval to critically ill newborns, despite agreeing to consider knee extensor muscle strength data for potential accelerated approval; in response, Stealth has implemented a 30% workforce reduction to conserve resources for the resubmission.

Analysis

Stealth BioTherapeutics faces a significant regulatory setback as the U.S. Food and Drug Administration (FDA) has requested a resubmission of the marketing application for its experimental therapy, elamipretide, intended for the rare genetic condition Barth syndrome. This 'complete response letter' follows a prolonged 16.5-month review period, which included an extension from January to April and a subsequent missed deadline by the FDA, underscoring the challenges in bringing elamipretide to market. The company had submitted mid-stage trial data indicating improvements in knee muscle strength, a metric the FDA has agreed to consider for accelerated approval. However, a critical point of contention remains the FDA's reluctance to extend this accelerated pathway to critically ill newborns, who notably constitute nearly two-thirds of the therapy's expanded access program participants. Barth syndrome affects fewer than 150 individuals in the U.S., with no currently approved treatments. In response to this development and to conserve resources for a potential resubmission, Stealth BioTherapeutics has implemented a 30% workforce reduction, a move reflecting the financial pressure and uncertainty introduced by the FDA's decision.

Key Decisions for Investors

• Investors should recognize the FDA's complete response letter as a material delay and heightened uncertainty for elamipretide's approval timeline, significantly impacting Stealth BioTherapeutics' near-term prospects.
• The 30% workforce reduction signals considerable financial strain; therefore, careful scrutiny of the company's cash burn rate and ability to fund a successful resubmission and potential further trials is warranted.
• The FDA's hesitation regarding the critically ill newborn population, a substantial portion of potential patients, poses a risk to the ultimate market size and commercial viability of elamipretide, even if approval for a narrower indication is eventually achieved.
• Monitor closely any further FDA communications, the specifics of the resubmission plan, and the company's strategy to address the agency's concerns, particularly regarding the data supporting efficacy and the target patient population.